Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.63 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in late spermatids | 0.75 |
| chemistry Open Targets | compounds already reach it: amoxapine, trifluoperazine hydrochloride, loxapine succinate +42 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 77 Parkinson's papers of 746 | 0.43 |
| pathways Reactome | 2 pathways; mostly dopamine synapse | 1.00 |
No case: the score is under the bar. Receipt 11447
Earlier readings: 2026-10-26 0.55; 2026-10-25 0.55; 2026-10-24 0.55; 2026-10-23 0.55.
Sealed predictions
- DRD3 in dopamine neurons, braak+0.77 (p 0.016) → -0.06 (p 0.879)receipt 0533
- DRD3 in dopamine neurons, braak+0.12 (p 0.446) → -0.10 (p 0.538)receipt 0042
- DRD3 in dopamine neurons, resilience-0.32 (p 0.181) → -0.12 (p 1.000)receipt 0043
Swarm cases
receipt 0533: DRD3 in dopamine neurons, braak
- power
- full sample +0.23 (p 0.355, n 18), 95% CI -0.26 to +0.63. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.19 (p 0.455, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.33 (p 0.182, n 18). could be the mix.
- skeptic
- leave-one-out range +0.11 to +0.31, sign flips 0; without severely affected donors +0.23 (p 0.355, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for DRD3 in dopamine neurons.
case closed: nothing better to follow up.
receipt 0043: DRD3 in dopamine neurons, resilience
- power
- full sample -0.29 (p 0.147, n 55), 95% CI -0.51 to -0.02. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for age, sex and PMI: -0.27 (p 0.171, n 55). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.12 (p 0.542); controlling for it: -0.26 (p 0.192, n 55). could be the mix.
- skeptic
- leave-one-out range -0.37 to -0.21, sign flips 0; without severely affected donors -0.31 (p 0.119, n 46). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "differs in resilient donors (Lewy pathology, no parkinsonism)" for DRD3 in dopamine neurons.
case closed: nothing better to follow up.
receipt 0042: DRD3 in dopamine neurons, braak
- power
- full sample +0.03 (p 0.805, n 84), 95% CI -0.19 to +0.24. the interval sits on zero: probably nothing there.
- confounder
- adjusted for age, sex and PMI: +0.02 (p 0.824, n 84). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis -0.72 (p 1.8e-14); controlling for it: +0.01 (p 0.956, n 84). could be the mix.
- skeptic
- leave-one-out range -0.01 to +0.06, sign flips 3; without severely affected donors +0.07 (p 0.523, n 75). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for DRD3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts